Predicting remission after acute phase pharmacotherapy in patients with bipolar I depression: A machine learning approach with cross‐trial and cross‐drug replication
Jean Marrero‐Polanco,Jeremiah B. Joyce,Caroline W. Grant,Paul E. Croarkin,Arjun P. Athreya,William V. Bobo
DOI: https://doi.org/10.1111/bdi.13506
2024-10-04
Bipolar Disorders
Abstract:Objectives Interpatient variability in bipolar I depression (BP‐D) symptoms challenges the ability to predict pharmacotherapeutic outcomes. A machine learning workflow was developed to predict remission after 8 weeks of pharmacotherapy (total score of ≤8 on the Montgomery Åsberg Depression Rating Scale [MADRS]). Methods Supervised machine learning models were trained on data from BP‐D patients treated with olanzapine (N = 168) and were externally validated on patients treated with olanzapine/fluoxetine combination (OFC; N = 131) and lamotrigine (LTG; N = 126). Top predictors were used to develop a prognosis rule informing how many symptoms should change and by how much within 4 weeks to increase the odds of achieving remission. Results An AUC of 0.76 (NIR:0.59; p = 0.17) was established to predict remission in olanzapine‐treated subjects. These trained models achieved AUCs of 0.70 with OFC (NIR:0.52; p
neurosciences,psychiatry,clinical neurology
What problem does this paper attempt to address?